×
About 1,073 results

ALLMedicine™ Oligodendroglioma Center

Research & Reviews  398 results

Integrated proteomic analysis of low-grade gliomas reveals contributions of 1p-19q co-d...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080204
Acta Neuropathologica Communications; Wong D, Lee TH et. al.

May 8th, 2022 - Diffusely infiltrative low-grade gliomas (LGG) are primary brain tumours that arise predominantly in the cerebral hemispheres of younger adults. LGG can display either astrocytic or oligodendroglial histology and do not express malignant histologi...

5-Aminolevulinic acid-enhanced fluorescence-guided treatment of high-grade glioma using...
https://doi.org/10.3171/2022.1.JNS212562
Journal of Neurosurgery; Strickland BA, Wedemeyer M et. al.

Mar 19th, 2022 - 5-Aminolevulinic acid (5-ALA)-enhanced fluorescence-guided resection of high-grade glioma (HGG) using microscopic blue light visualization offers the ability to improve extent of resection (EOR); however, few descriptions of HGG resection performe...

Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919570
Molecular Medicine (Cambridge, Mass.); Zhao B, Xia Y et. al.

Mar 16th, 2022 - IDH-mutant astrocytoma and oligodendroglioma have an indolent natural history and are recognized as distinct entities of neoplasms. There is little knowledge on the molecular differences between IDH-mutant astrocytoma and oligodendroglioma grade 2...

see more →

Guidelines  4 results

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
https://doi.org/10.1200/JCO.21.02036
Journal of Clinical Oncology : Official Journal of the Am... Mohile NA, Messersmith H et. al.

Dec 14th, 2021 - To provide guidance to clinicians regarding therapy for diffuse astrocytic and oligodendroglial tumors in adults. ASCO and the Society for Neuro-Oncology convened an Expert Panel and conducted a systematic review of the literature. Fifty-nine rand...

The role of initial chemotherapy for the treatment of adults with diffuse low grade gli...
https://doi.org/10.1007/s11060-015-1931-x
Journal of Neuro-oncology; Ziu M, Kalkanis SN et. al.

Nov 5th, 2015 - Adult patients (older than 18 years of age) with newly diagnosed World Health Organization (WHO) Grade II gliomas (Oligodendroglioma, astrocytoma, mixed oligoastrocytoma). Is there a role for chemotherapy as adjuvant therapy of choice in treatment...

The role of surgery in the management of patients with diffuse low grade glioma: A syst...
https://doi.org/10.1007/s11060-015-1867-1
Journal of Neuro-oncology; Aghi MK, Nahed BV et. al.

Nov 5th, 2015 - Should patients with imaging suggestive of low grade glioma (LGG) undergo observation versus treatment involving a surgical procedure? These recommendations apply to adults with imaging suggestive of a WHO grade 2 glioma (oligodendroglioma, astroc...

Central nervous system cancers.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124889
Journal of the National Comprehensive Cancer Network : JN... Nabors LB, Ammirati M et. al.

Sep 14th, 2013 - Primary and metastatic tumors of the central nervous system are a heterogeneous group of neoplasms with varied outcomes and management strategies. Recently, improved survival observed in 2 randomized clinical trials established combined chemothera...

see more →

Clinicaltrials.gov  10 results

NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma
https://clinicaltrials.gov/ct2/show/NCT03353896

Dec 10th, 2020 - PRIMARY OBJECTIVES: I. To describe the safety and tolerability of the TTFields treatment in patients with newly diagnosed high risk oligodendroglioma following standard of care treatment. SECONDARY OBJECTIVES: I. To estimate the proportion of pati...

Fenretinide in Treating Patients With Recurrent Malignant Glioma
https://clinicaltrials.gov/ct2/show/NCT00006080

Jun 27th, 2018 - OBJECTIVES: I. Determine the efficacy of fenretinide as assessed by 6-month progression- free survival in patients with recurrent malignant glioma. II. Determine the rate of measurable clinical response, time to progression, and overall survival o...

Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma
https://clinicaltrials.gov/ct2/show/NCT00002569

Jun 18th, 2018 - OBJECTIVES: Compare the overall survival and time to tumor progression in patients with unifocal or multifocal, supratentorial, pure or mixed anaplastic oligodendroglioma treated with radiotherapy with or without procarbazine, lomustine, and vincr...

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma
https://clinicaltrials.gov/ct2/show/NCT00003472

Mar 21st, 2018 - OVERVIEW: This is a single arm, open-label study in which adults with recurrent/progressive oligodendrogliomas receive gradually escalating doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is rea...

ROCOCO - Low Grade Glioma - Planning Study
https://clinicaltrials.gov/ct2/show/NCT02607397

Mar 28th, 2017 - Patients with low grade glioma have a far better prognosis than patients with high grade glioma. Despite their low incidence and initial favorable biological behavior, low-grade gliomas are behaving as malignant brain tumours leading to considerab...

see more →

News  14 results

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

Brain Tumors Exact Higher Mortality Toll in Men Than Women
https://www.medscape.com/viewarticle/968594

Feb 15th, 2022 - New research shows that men in their 20s and 30s have worse survival from many different types of brain tumors than women of the same age. And, researchers say, it’s not exactly clear why. Differences in treatment may mediate some of the associati...

Dr. Verhaak Discusses Genomic Characterization of Diffuse Lower Grade Gliomas
https://www.onclive.com/view/roeland-gw-verhaak-phd-discusses-genomic-characterization-of-diffuse-lower-grade-gliomas

Dec 20th, 2020 - Roeland GW Verhaak, PhD, Assistant Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the comprehensive and integ...

PCV Chemotherapy Plus Radiation Improves Survival in Low-Grade Glioma
https://www.onclive.com/view/pcv-chemotherapy-plus-radiation-improves-survival-in-low-grade-glioma

Dec 20th, 2020 - Jan C. Buckner, MD In a phase III study, a combination of radiation therapy and procarbazine, CCNU, and vincristine (PCV) prolonged both overall survival (OS) and progression-free survival (PFS) compared with radiation therapy (RT) alone for pati...

AG-120 Shows Early Efficacy in IDH1-Mutant Glioma
https://www.onclive.com/view/ag120-shows-early-efficacy-in-idh1mutant-glioma

Dec 20th, 2020 - Ingo K. Mellinghoff, MD Treatment with AG-120 at an established dose of 500 mg induced a stable disease rate of 83% and a minor response rate of 9% for patients with non-enhancing IDH1-mutated glioma, according to findings from an expansion cohor...

see more →

Patient Education  3 results see all →